Sign up USA
Proactive Investors - Run By Investors For Investors

Q BioMed says all convertible notes and loans now settled

Last month, hares rose as it welcomed an autism language expert to its advisory committee
Q BioMed says all convertible notes and loans now settled
The company is interested in various biotech assets

Q BioMed Inc (OTCQB: QBIO), a biotechnology acceleration company, said all its convertible notes and loans have been settled in full.

The company ended its 2017 financial year with no outstanding loans or convertible debt, it added.

"We are very pleased to end the fiscal year with a strong balance sheet and with a solid capital and financial structure from which to continue to build our business," said Denis Corin, chief executive.

Last month,  the company's shares rose as it welcomed an autism language expert to its  advisory committee for its candidate for non-verbal disorder in toddlers.

Dr Helen Tager-Flusberg has provided the protocol for capturing the primary endpoint of the planned trial for QBM-001.

Around 20,000 new cases of the disorder  are diagnosed in the USA each year and a similar amount in Europe.

The condition is one that affects very young (1 to 2yrs of age) children who are on the autistic spectrum.

The result is known as a ‘non-verbal disorder’ and is accompanied with developmental delay, where the toddlers either never learn to speak or lose the ability to speak.

Q Biomed Inc shares eased 1.27% to US$4.65 on the day.

View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
October 23 2017
The company is poised for a milestone-rich period over the next year or so

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use